How Does Menopause Affect Biological Aging and Long-Term Health Outcomes?

The short answer

Menopause — the permanent cessation of menstruation — is associated with accelerated bone loss (3–5% per year in the first 5 years post-menopause), increased cardiovascular risk, and cognitive changes due to oestrogen withdrawal. Menopausal hormone therapy (MHT) effectively addresses these changes but carries risks that must be weighed against benefits based on individual health profiles.

What the evidence actually shows

The Women's Health Initiative (WHI) trial (Rossouw et al., 2002) was the largest RCT of MHT, finding that combined oestrogen-progestogen therapy increased breast cancer risk by 26% and cardiovascular events in older postmenopausal women. However, subsequent re-analysis (Manson et al., 2013) showed that the timing of MHT initiation is critical — women who started MHT within 10 years of menopause (the 'timing hypothesis') had lower cardiovascular mortality, while those starting more than 20 years post-menopause had higher risk. MedlinePlus notes that menopause is associated with increased risk of osteoporosis, heart disease, and urinary problems, and that MHT can help with symptoms and bone loss but carries risks.

"Women who initiated hormone therapy within 10 years of menopause had lower cardiovascular mortality than those who initiated it later — the 'timing hypothesis.'"

— Manson et al., NEJM 2013

What the major health authorities say

MedlinePlus identifies menopause as a natural transition associated with increased health risks, and notes that MHT can help with symptoms and bone loss but should be used at the lowest effective dose for the shortest time needed. The International Menopause Society (IMS) recommends that MHT is appropriate for women under 60 or within 10 years of menopause who have bothersome symptoms or are at elevated risk of osteoporosis, in the absence of contraindications. The NIA recommends discussing MHT with a healthcare provider to weigh individual risks and benefits.

Practical implications

For women experiencing significant menopausal symptoms (hot flushes, sleep disruption, urogenital symptoms) or at high risk of osteoporosis, MHT initiated within 10 years of menopause and before age 60 has a favourable risk-benefit profile for most women without contraindications (history of breast cancer, unexplained vaginal bleeding, active liver disease, or thromboembolic disease). Non-hormonal strategies for bone health (weight-bearing exercise, calcium, vitamin D) and cardiovascular risk (DASH diet, aerobic exercise) are important regardless of MHT status.

Where reasonable people still disagree

• Whether the cardiovascular benefits of early MHT initiation are sufficient to justify its use for primary cardiovascular prevention in otherwise healthy postmenopausal women.
• The long-term breast cancer risk of different MHT formulations (oestrogen-only vs combined, oral vs transdermal, different progestogens).
• Whether bioidentical hormone preparations offer a different risk-benefit profile compared to conventional MHT.